Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Jaro1977on Mar 19, 2021 2:09pm
206 Views
Post# 32839169

RE:RE:RE:RE:RE:RE:RE:10 patients early 2021 for 25 for Breakthrough Designation

RE:RE:RE:RE:RE:RE:RE:10 patients early 2021 for 25 for Breakthrough Designation Thanks for the link, I had read them. It was just a bit confusing:
14 patients as primary
5 maint (what does that mean). Treated properly and done?

I think this a yes above.

5 removed (why?)

They had some condition that seemed to disallow them to be in the trial however, after discovery of the miss dose, I think that they could have remained in the trial.  Not 100% sure.

Remaining 9.
At 90 day, 3 were complete responders, 3 non responders, 2 partial, 1 TBD

At 180, 4 complete (is that the first 3 plus 1 from which category in 90 day
At 180, non-responder is now just 1, so does that mean 2 converted to responder? Sounds great if that is what it means.

It should mean that the treatment is now working for the patient after the 2nd treatment.

At 180, 2 are now TBD...how does TBD increase from 90 to 180 days?

I guess it means no change, not working for them for whatever reason.

I really don't mean to ask dumb questions. I really have read as much as can find.

The only dumb question is the one that is not asked.
<< Previous
Bullboard Posts
Next >>